BIOCYTOGEN-B (02315) Rises Over 5% Again, Recently Added to Stock Connect List, Institutions Say "Thousand Mice Ten Thousand Antibodies" Strategy Begins Paying Off

Stock News2025-12-31

BIOCYTOGEN-B (02315) surged more than 5% again. As of the time of writing, the stock was up 4.94% to HK$36.08, with a turnover of HK$27.5841 million. On the news front, the Shanghai Stock Exchange and the Shenzhen Exchange recently announced that BIOCYTOGEN will be added to the Stock Connect list, effective from December 24, 2025. This move marks another significant milestone following the company's establishment of a dual capital market platform with "A+H" shares, fully opening its Hong Kong stock channel to mainland investors henceforth. Huafu Securities noted in a previous research report that the company's "Thousand Mice Ten Thousand Antibodies" initiative is beginning to yield results, with antibody licensing driving an earnings explosion. Considering the company's high-growth business profile and strong competitive moat, its solid foundational preclinical animal and pharmacological efficacy evaluation business, and the antibody development segment gradually entering a phase of performance realization, coupled with the potential of its novel drug pipeline, the institution initiated coverage with a "Buy" rating.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1132183254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-31 10:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1132183254","market":"us","top_or_hot":-1,"title":"BIOCYTOGEN-B (02315) Rises Over 5% Again, Recently Added to Stock Connect List, Institutions Say \"Thousand Mice Ten Thousand Antibodies\" Strategy Begins Paying Off","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) surged more than 5% again. As of the time of writing, the stock was up 4.94% to HK$36.08, with a turnover of HK$27.5841 million.\nOn the news front, the Shanghai Stock Exchange and the Shenzhen Exchange recently announced that BIOCYTOGEN will be added to the Stock Connect list, effective from December 24, 2025.\nThis move marks another significant milestone following the company's establishment of a dual capital market platform with \"A+H\" shares, fully opening its Hong Kong stock channel to mainland investors henceforth.\nHuafu Securities noted in a previous research report that the company's \"Thousand Mice Ten Thousand Antibodies\" initiative is beginning to yield results, with antibody licensing driving an earnings explosion.\nConsidering the company's high-growth business profile and strong competitive moat, its solid foundational preclinical animal and pharmacological efficacy evaluation business, and the antibody development segment gradually entering a phase of performance realization, coupled with the potential of its novel drug pipeline, the institution initiated coverage with a \"Buy\" rating.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B (02315) Rises Over 5% Again, Recently Added to Stock Connect List, Institutions Say \"Thousand Mice Ten Thousand Antibodies\" Strategy Begins Paying Off</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B (02315) Rises Over 5% Again, Recently Added to Stock Connect List, Institutions Say \"Thousand Mice Ten Thousand Antibodies\" Strategy Begins Paying Off\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-31 10:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) surged more than 5% again. As of the time of writing, the stock was up 4.94% to HK$36.08, with a turnover of HK$27.5841 million.\nOn the news front, the Shanghai Stock Exchange and the Shenzhen Exchange recently announced that BIOCYTOGEN will be added to the Stock Connect list, effective from December 24, 2025.\nThis move marks another significant milestone following the company's establishment of a dual capital market platform with \"A+H\" shares, fully opening its Hong Kong stock channel to mainland investors henceforth.\nHuafu Securities noted in a previous research report that the company's \"Thousand Mice Ten Thousand Antibodies\" initiative is beginning to yield results, with antibody licensing driving an earnings explosion.\nConsidering the company's high-growth business profile and strong competitive moat, its solid foundational preclinical animal and pharmacological efficacy evaluation business, and the antibody development segment gradually entering a phase of performance realization, coupled with the potential of its novel drug pipeline, the institution initiated coverage with a \"Buy\" rating.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1132183254","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1132183254","pubTimestamp":1767147021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) surged more than 5% again. As of the time of writing, the stock was up 4.94% to HK$36.08, with a turnover of HK$27.5841 million. On the news front, the Shanghai Stock Exchange...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688796":"百奥赛图","BK0216":"研究试验","BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"百奥赛图-B(02315)再涨超5%，近期新增沪股通名单，机构称“千鼠万抗”策略开始见成效","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688796":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) surged more than 5% again. As of the time of writing, the stock was up 4.94% to HK$36.08, with a turnover of HK$27.5841 million.\nOn the news front, the Shanghai Stock Exchange and the Shenzhen Exchange recently announced that BIOCYTOGEN will be added to the Stock Connect list, effective from December 24, 2025.\nThis move marks another significant milestone following the company's establishment of a dual capital market platform with \"A+H\" shares, fully opening its Hong Kong stock channel to mainland investors henceforth.\nHuafu Securities noted in a previous research report that the company's \"Thousand Mice Ten Thousand Antibodies\" initiative is beginning to yield results, with antibody licensing driving an earnings explosion.\nConsidering the company's high-growth business profile and strong competitive moat, its solid foundational preclinical animal and pharmacological efficacy evaluation business, and the antibody development segment gradually entering a phase of performance realization, coupled with the potential of its novel drug pipeline, the institution initiated coverage with a \"Buy\" rating.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1132183254","isCrawlerRequest":true}